filmov
tv
Patients with refractory metastatic colorectal cancer experience survival benefits with fruquintinib
Показать описание
#colorectalcancer #cancerresearch
Researchers from The University of Texas MD Anderson Cancer Center reported study results showing that the targeted therapy fruquintinib significantly improved overall survival (OS) and progression-free survival (PFS) in patients with refractory metastatic colorectal cancer.
Follow us on
Researchers from The University of Texas MD Anderson Cancer Center reported study results showing that the targeted therapy fruquintinib significantly improved overall survival (OS) and progression-free survival (PFS) in patients with refractory metastatic colorectal cancer.
Follow us on
0:02:39
0:03:15
0:00:54
0:06:23
0:03:06
0:06:54
0:04:58
0:03:33
0:07:35
0:03:04
0:02:36
0:03:43
0:07:32
0:08:14
0:21:59
0:01:23
0:04:54
0:09:12
0:07:11
0:05:30
0:01:30
0:07:20
0:08:45
0:06:26